The addition of nintedanib to pemetrexed/cisplatin appeared safe and effective for the treatment of patients with malignant pleural mesothelioma, according to results from the LUME-Meso trial presented at International Association for the Study of Lung Cancer Multidisciplinary Symposium in Thoracic Oncology.
Nintedanib (Ofev, Boehringer Ingelheim) is an intracellular inhibitor that targets multiple tyrosine kinases, including VEGFR 1–3, PDGFR /, FGFR 1–3, Src and Abl.
“Nintedanib strongly inhibits malignant pleural mesothelioma tumor growth in human xenograft models and reduces the colony-forming capacity and migratory activity of malignant pleural mesothelioma cell lines,” José Barrueco, executive director of global clinical development of oncology at Boehringer Ingelheim, said during the presentation.Barrueco and colleagues conducted the phase 2/phase 3 double-blind, randomized LUME-Meso trial to evaluate the combination of nintedanib plus pemetrexed/cisplatin in chemotherapy-naive patients with unresectable malignant pleural mesothelioma.[Article continues at original source]
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.